# Tobramycin in Bronchiectasis Colonized With Pseudmonas Aeruginosa

> **NCT03715322** · PHASE3 · UNKNOWN · sponsor: **Guangzhou Institute of Respiratory Disease** · enrollment: 350 (estimated)

## Conditions studied

- Bronchiectasis Adult
- Pseudomonas Infections

## Interventions

- **DRUG:** Tobramycin Inhalant Product
- **OTHER:** usual care
- **DRUG:** Natural saline inhalation

## Key facts

- **NCT ID:** NCT03715322
- **Lead sponsor:** Guangzhou Institute of Respiratory Disease
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-10-26
- **Primary completion:** 2021-04
- **Final completion:** 2021-06
- **Target enrollment:** 350 (ESTIMATED)
- **Last updated:** 2019-08-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03715322

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03715322, "Tobramycin in Bronchiectasis Colonized With Pseudmonas Aeruginosa". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03715322. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*